AB21844

FITC Anti-CD22 antibody [IS7]

Be the first to review this product! 리뷰 제출

(1 출판물)

Anti-CD22 antibody [IS7] conjugated to FITC - suitable for flow cytometry, and reacts with human samples. Clone [IS7] is a mouse monoclonal antibody.

Design your panel with our interactive flow cytometry panel builder. Click here.

1 이미지

Flow Cytometry - FITC Anti-CD22 antibody [IS7] (AB21844)

Flow Cyt

Unknown

Flow Cytometry - FITC Anti-CD22 antibody [IS7] (AB21844)

Overlay histogram showing peripheral blood lymphocytes stained with ab21844 (red line). The cells incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab21844, 0.5 μg/1x10⁶ cells) for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 FITC (2 μg/1x10⁶ cells ) for 30 min at 22°C. Acquisition of >5,000 events was performed.

주요 정보

Host species

Mouse

Clonality

Monoclonal

Clone number

IS7

Isotype

IgG1

Conjugation

FITC

Excitation/Emission

Ex: 495nm, Em: 519nm

Carrier free

Reacts with

Human

Applications

Flow Cyt

applications

Immunogen

Cell preparation containing CD22 protein. The exact immunogen used to generate this antibody is proprietary information.

P20273

style

left-column

style

left-column

Reactivity 정보

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "4.15 µL for 10^6 Cells", "FlowCyt-species-notes": "<p><a href='/ko/products/primary-antibodies/fitc-mouse-igg1-b11-6-isotype-control-ab91356'>ab91356</a> - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.</p>" }, "Primates": { "FlowCyt-species-checked": "predicted", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "" } } }

style

left-column

제품 세부 정보

The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC and adjusted for direct use. No reconstitution is necessary.

style

left-column

특성 및 보관 정보

제형

Liquid

Purification 테크닉

Affinity purification Protein G

보관 버퍼

pH: 7.4 Preservative: 0.097% Sodium azide Constituents: BSA, PBS

배송 시 보관 조건

Blue Ice

적절한 단기 보관 조건

+4°C

적절한 장기 보관 조건

+4°C

style

left-column

추가 정보

This supplementary information is collated from multiple sources and compiled automatically.

CD22 also known as Siglec-2 or B-lymphocyte cell adhesion molecule (BL-CAM) is a transmembrane protein with a mass of around 140 kDa. It is selectively expressed on the surface of mature B cells and some immature B cells. This protein plays an important role in the immune system particularly in the regulation of B cell function. CD22 functions by modulating signal transduction processes through its cytoplasmic domain which contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs).

Biological function summary

CD22 acts mainly as a negative regulator of B cell receptor (BCR) signaling. It is part of a complex that interacts with the BCR and other accessory molecules. CD22 helps maintain B cell tolerance by inhibiting overactive signaling and preventing autoimmune responses. By binding to sialic acid-containing glycans CD22 modulates interactions between B cells and other cells aiding in the maintenance of immune homeostasis.

Pathways

CD22 plays a critical role in the BCR signaling pathway and the regulation of phosphatidylinositol 3-kinase (PI3K) signaling. It works together with proteins like CD19 and SHP-1 that are key components of these pathways. By influencing these signaling cascades CD22 contributes to the modulation of B cell activation proliferation and apoptosis ensuring proper functioning of the immune response.

CD22 is associated with autoimmune conditions and hematological malignancies such as hairy cell leukemia (HCL). Therapeutic approaches targeting CD22 such as anti-CD22 antibodies are being explored for treating these diseases. CD22's role in these conditions is connected with proteins involved in the autoimmune pathways or cancer development offering potential therapeutic targets for intervention.

style

left-column

style

left-column

제품 프로토콜

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

타겟 정보

Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow (PubMed : 34330755, PubMed : 8627166). Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration (PubMed : 20172905). Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling (PubMed : 8627166). If this negative signaling from is of sufficient strength, apoptosis of the B-cell can be induced (PubMed : 20516366).

See full target information CD22

대체 명칭 보기

CD22, SIGLEC2, B-cell receptor CD22, B-lymphocyte cell adhesion molecule, Sialic acid-binding Ig-like lectin 2, T-cell surface antigen Leu-14, BL-CAM, Siglec-2

style

left-column

제품이 사용된 논문 (1)

Recent publications for all applications. Explore the 전체 목록 and refine your search

Oncology letters 27:14 PubMed38028179

2023

CBX7 is involved in the progression of cervical cancer through the ITGβ3/TGFβ1/AKT pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Ping Tian,Jinglan Deng,Cailing Ma,Ainipa Miershali,Gulikezi Maimaitirexiati,Qi Yan,Yating Liu,Hatimihan Maimaiti,Yuting Li,Changhui Zhou,Jingqin Ren,Lu Ding,Rong Li

제품이 사용된 논문 모두 보기

style

left-column

style

left-column

style

right-column

Product promise

저희는 고품질 시약으로 고객님의 연구를 서포트하고자 최선을 다하고 있으며, 모든 단계에서 함께 하겠습니다. 만약 제품이 기대한 성능을 보이지 않을 경우에도 Product Promise로 보호받으실 수 있습니다.

자세한 내용은 이용 약관을 확인해 주세요.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

FITC Anti-CD22 antibody [IS7]

Flow Cytometry - FITC Anti-CD22 antibody [IS7] (AB21844)

관련 conjugated 항체와 다양한 조성의 항체 (3)

주요 정보

Host species

Clonality

Clone number

Isotype

Conjugation

Excitation/Emission

Carrier free

Reacts with

Applications

Immunogen

대체품

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

보완 제품

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Reactivity 정보

제품 세부 정보

특성 및 보관 정보

제형

Purification 테크닉

보관 버퍼

배송 시 보관 조건

적절한 단기 보관 조건

적절한 장기 보관 조건

추가 정보

Biological function summary

Pathways

제품 프로토콜

타겟 정보

대체 명칭 보기

제품이 사용된 논문 (1)

Product promise